Fennec Pharmaceuticals (TSE:FRX) Stock Passes Above 50 Day Moving Average of $13.11

Fennec Pharmaceuticals Inc. (TSE:FRXGet Rating)’s share price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$13.11 and traded as high as C$13.26. Fennec Pharmaceuticals shares last traded at C$13.26, with a volume of 357 shares traded.

Analyst Ratings Changes

FRX has been the topic of several recent research reports. HC Wainwright restated a “buy” rating on shares of Fennec Pharmaceuticals in a research report on Thursday, October 20th. Cantor Fitzgerald raised Fennec Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Tuesday, November 22nd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Fennec Pharmaceuticals has an average rating of “Buy” and an average target price of C$10.00.

Fennec Pharmaceuticals Trading Down 1.1 %

The company has a debt-to-equity ratio of 881.09, a quick ratio of 10.17 and a current ratio of 10.30. The firm has a market capitalization of C$348.22 million and a price-to-earnings ratio of -16.21. The company has a 50 day moving average price of C$13.11 and a two-hundred day moving average price of C$10.90.

Fennec Pharmaceuticals (TSE:FRXGet Rating) last posted its quarterly earnings data on Friday, November 11th. The biopharmaceutical company reported C($0.40) EPS for the quarter, missing the consensus estimate of C($0.23) by C($0.17).

Fennec Pharmaceuticals Company Profile

(Get Rating)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014.

Further Reading

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.